Although randomized data are still pending, several studies suggest an anti-cancer effect and better post-transplant survivals with the use of mammalian target of rapamycin (mTOR) inhibitors, and patients may be put on such drugs when a recurrence occurs [6, 7, 19, 20]. This evidence concerns the gene MTOR and cancer.